title: Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapy.
authors.affiliation: Thoracic Department, Marie Lannelongue Surgical Center, Le Plessis Robinson, 92350, France.
authors.forename: P
authors.initials: P
authors.lastname: Pradere
authors.affiliation: Drug Development Department, Gustave Roussy Institute, Villejuif, 94805, France.
authors.forename: J M
authors.initials: JM
authors.lastname: Michot
authors.affiliation: Drug Development Department, Gustave Roussy Institute, Villejuif, 94805, France.
authors.forename: S
authors.initials: S
authors.lastname: Champiat
authors.affiliation: Drug Development Department, Gustave Roussy Institute, Villejuif, 94805, France.
authors.forename: F X
authors.initials: FX
authors.lastname: Danlos
authors.affiliation: Drug Development Department, Gustave Roussy Institute, Villejuif, 94805, France.
authors.forename: A
authors.initials: A
authors.lastname: Marabelle
authors.affiliation: APHP, Internal Medicine and Clinical Immunology Department, Bicêtre Hospital, AP-HP, Le Kremlin Bicêtre, 94270, France; Université Paris Sud, 63 rue Gabriel Péri, 94276 Le Kremlin Bicêtre, France.
authors.forename: O
authors.initials: O
authors.lastname: Lambotte
authors.affiliation: Medical Oncology Department, Gustave Roussy Institute, Villejuif, 94805, France.
authors.forename: L
authors.initials: L
authors.lastname: Albiges
authors.affiliation: Thoracic Department, Marie Lannelongue Surgical Center, Le Plessis Robinson, 92350, France.
authors.forename: J
authors.initials: J
authors.lastname: Le Pavec
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D001229:Aspergillosis, Allergic Bronchopulmonary / Q000139:chemically induced*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D007211:Indoles / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008875:Middle Aged; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors / Q000276:immunology*; D011758:Pyrroles / Q000627:therapeutic use; D000077210:Sunitinib
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D007211:Indoles; D061026:Programmed Cell Death 1 Receptor; D011758:Pyrroles; D000077210:Sunitinib